Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Total Non-Current Liabilities: 2010-2025

Historic Total Non-Current Liabilities for Lifecore Biomedical (LFCR) over the last 14 years, with May 2025 value amounting to $166.9 million.

  • Lifecore Biomedical's Total Non-Current Liabilities fell 4.43% to $166.9 million in Q2 2025 from the same period last year, while for May 2025 it was $166.9 million, marking a year-over-year decrease of 4.43%. This contributed to the annual value of $166.9 million for FY2025, which is 4.43% down from last year.
  • As of FY2025, Lifecore Biomedical's Total Non-Current Liabilities stood at $166.9 million, which was down 4.43% from $174.7 million recorded in FY2024.
  • In the past 5 years, Lifecore Biomedical's Total Non-Current Liabilities registered a high of $297.1 million during FY2021, and its lowest value of $153.6 million during FY2023.
  • Over the past 3 years, Lifecore Biomedical's median Total Non-Current Liabilities value was $166.9 million (recorded in 2025), while the average stood at $165.0 million.
  • As far as peak fluctuations go, Lifecore Biomedical's Total Non-Current Liabilities plummeted by 37.16% in 2022, and later grew by 13.74% in 2024.
  • Lifecore Biomedical's Total Non-Current Liabilities (Yearly) stood at $297.1 million in 2021, then tumbled by 37.16% to $186.7 million in 2022, then decreased by 17.75% to $153.6 million in 2023, then grew by 13.74% to $174.7 million in 2024, then dropped by 4.43% to $166.9 million in 2025.